Asahi Chemical Trains Apheresis Specialists For Chinese Hospitals
This article was originally published in PharmAsia News
Executive SummaryTokyo-based medical device maker Asahi Chemical Kuraray Medical established the Apheresis Training Center in Beijing. In collaboration with Captial Medical University's Youan Hospital, Asahi Chemical will use the center to train physicians and nurses for apheresis and dialysis treatments in Chinese hospitals. Youan Hospital has used apheresis to treat over 18,000 patients with liver disease, and apheresis is gaining popularity in China as a key treatment for patients with multi-organ failure, liver failure and intractable autoimmune disorders. The company also plans to launch satellite training centers in other major Chinese cities such as Shanghai and Guangzhou. Asahi also looks to establish similar training facilities in the U.S. and Canada. (Click here for more - Japanese language
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.